Was Jim Cramer Right About Novo Nordisk A/S (NVO)?

We recently published a list of Was Jim Cramer Right About These 9 Stocks?. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses.

In a prior call, a viewer asked about Novo Nordisk A/S (NYSE:NVO) as a long-term growth stock. Cramer gave it credit but made it clear he preferred Eli Lilly due to a promising Alzheimer’s-related drug in its pipeline. He said:

“NVO is a good growth stock… but I like Lilly better because Lilly may have, and it hasn’t happened yet, a little bit of a kick from another drug that it’s working on involving dementia… and I sure hope they solve it, but we’ve not seen anything about it yet.”

The pharma stock did not prove to be a growth stock at all, as it has declined by -49.32% since.

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based pharmaceutical company that specializes in diabetes care, obesity treatments, and hormone replacement therapies.

Cramer continues to like Eli Lilly better. Here’s  what he said about Novo on May 2:

“Next, did Novo Nordisk deliver a knockout punch to Eli Lilly when it signed a deal to be the preferred GLP-1 supplier to CVS on Lilly’s earnings day, no less? What a comeuppance. I think there’s plenty of gas in the Lily tank, especially once it tells it’s, you know, once it’s got this pill formulation that’s going to be available next year. I think it’s going to matter tremendously.”

Overall, NVO ranks 9th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.